相关实验视频

Updated: May 7, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

酸抑制了NLRP3炎症酶激活通过Nrf2激活在糖尿病脏病的激活

Liping Bao¹, Yuhan Gong¹, Wenji Xu²

¹Department of Nephrology, Pu'er People's Hospital, Pu'er, Yunnan, China.

|January 6, 2025

概括

酸 (CGA) 通过抑制NLRP3炎症酶激活来减缓糖尿病病 (DN) 的进展. 这种效应与调节Nrf2通路有关,这表明CGA是CGA.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

糖尿病病 (DN) 是末期病 (ESRD) 的主要原因之一.
炎症 (NLRP3炎症酶) 和氧化应激 (Nrf2通路) 是DN的关键驱动因素.
迫切需要针对DN的新型治疗策略.

研究的目的:

在糖尿病大鼠模型中评估酸 (CGA) 的脏保护作用.
阐明CGA在DN中的作用背后的抗炎机制.
研究CGA在调节Nrf2和NLRP3炎症细胞通路中的作用.

主要方法:

建立糖尿病老鼠模型,以评估CGA在体内的疗效.
测量血清肌素 (Scr),血液尿素 (BUN) 和尿路蛋白质分泌.
在体外实验中使用Nrf2siRNA来确认途径的参与.

主要成果:

在糖尿病大鼠中,CGA的使用显著降低了Scr,BUN和尿蛋白水平.
CGA激活了Nrf2通路,并抑制了NLRP3炎症酶激活.
Nrf2 siRNA转染在体外消除了CGA对NLRP3炎症酶激活的抑制作用.

结论:

酸 (CGA) 显示出针对糖尿病病 (DN) 的显著保护作用.
CGA的治疗作用包括通过Nrf2通路调节抑制NLRP3炎症酶激活.
CGA具有作为治疗糖尿病病管理的治疗剂的潜力.

更多相关视频

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...